New drug duo aims to fight tough liver cancer
NCT ID NCT07490262
Summary
This study is testing whether a combination of two immunotherapy drugs, IBI310 and sintilimab, can help people with advanced liver cancer that cannot be removed by surgery. It will involve about 680 adults who have not yet received any drug treatment for their cancer. The main goals are to see if the drug combo helps patients live longer and keeps the cancer from getting worse, while also checking for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hosptial of USTC
Hefei, Anhui, 230001, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.